Please login to the form below

Not currently logged in


This page shows the latest deflazacort news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer unimpressed with PTC’s Translarna

FDA reviewer unimpressed with PTC’s Translarna

saying its commercial operations were already in gear following the FDA’s approval of Emflaza (deflazacort) for DMD earlier this year.

Latest news

  • Connecting the dots Connecting the dots

    Not just any drug mind you - a decades-old corticosterioid called Emflaza (deflazacort) that is available elsewhere for about $1, 500 per year.

  • Marathon pauses Emflaza launch amid pricing furore Marathon pauses Emflaza launch amid pricing furore

    In a nutshell, they want Marathon to justify its claim that the cost of developing Emflaza for DMD warrants that price tag, given that deflazacort a is "widely available abroad for

  • FDA approves first steroid for Duchenne muscular dystrophy FDA approves first steroid for Duchenne muscular dystrophy

    Emflaza (deflazacort) is the first corticosteroid to be approved by the FDA to treat DMD, said the US agency in a statement. ... Complicating the picture is that deflazacort has been available outside the US for decades and patients have been able to

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    230. Marathon. PTC Therapeutics. Product acquisition. Emflaza (deflazacort), marketed for Duchenne Muscular Dystrophy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...